All In MedTech

Device Trial Radar · NCT03857919

TearCare System to Treat Dry Eye Disease

Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare® System in the Treatment of the Signs and Symptoms of Dry Eye Disease

Last checked: Nov 20, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 235 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

235

Actual

Start

Mar 3, 2019

Primary completion

Feb 17, 2020

Study completion Dec 18, 2020

Sponsor

Lead sponsor
Sight Sciences, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Feb 28, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the TearCare System will be compared with the LipiFlow Thermal Pulsation System in patients with dry eye disease. The objective is to demonstrate that the TearCare System is safe and effective in relieving the signs and symptoms of dry eye disease.

Conditions

  • Dry Eye
  • Meibomian Gland Dysfunction

Interventions

  • TearCareDevice

    The TearCare SmartLids will be applied to the external surface of each eyelid. The TearCare System will be turned on and heat will be delivered to the eyelids for 15 minutes. Immediately following the thermal portion of the procedure, the SmartLids will be removed and the doctor will manually express the meibomian glands.

  • LipiFlowDevice

    The LipiFlow activators will be placed between the inner eyelid and the corneal surface of each eye. The LipiFlow System will be turned on and heat and pressure will be delivered to each eyelid for 12 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Tear Break-Up Time (TBUT) From BaselineTime frame: 1 month

1 more outcomes with a free account

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Schwartz Laser Eye Center

    Scottsdale, Arizona

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.